Eckert & Ziegler AG. (11/14/23). "Press Release: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes". Berlin.

	Region	Shanghai
	Country	China
	Organisation	Qi Kang Medical Technology (Changzhou) Co., Ltd.
	Group	Eckert & Ziegler (Group)
	Organisation 2	Eckert & Ziegler Strahlen- und Medizintechnik AG
	Today	Eckert & Ziegler SE
	Group	Eckert & Ziegler (Group)
	Product	RADIOPHARMACEUTICAL (RPT)
	Product 2	lutetium-177 (medical isotope)
	Person	Riehle, Karolin (Eckert & Ziegler 202212 Investor Relations + PR)

Insider information pursuant to Article 17 MAR

Eckert & Ziegler (ISIN DE0005659700) strengthens its competitive position in the growth market of China and today signed a 50:50 joint venture agreement with the Chinese pharmaceutical company DongCheng Pharma (DC Pharma).

Eckert & Ziegler will benefit from the cooperation between the two companies above all at its production site in Jintan near Shanghai. Here, the radioisotopes urgently needed for cancer diagnostics and therapy on the growing Chinese market shall be produced and commercialized.

DC Pharma invests € 20 million in the EZAG subsidiary Qi Kang Medical Technology (Changzhou) Co., Ltd. by way of a capital increase and will subsequently hold 50% of the shares.

The joint venture will complete the production facility currently under construction in Jintan and start the production of cyclotron-based isotopes in a first phase. In a second phase, further production lines for radioisotopes such as Lu-177 are to follow.

DC Pharma is one of the leading radiopharmaceutical companies in China with sales of 498 million US$ or 3.6 billion CNY (2022). With its market position, experience in production and sales, it is the ideal partner for Eckert & Ziegler.

Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

Record changed: 2024-01-31